• Theratechnologies Inc., of Montreal, said it has filed a final short-form base shelf prospectus and the prospectus supplement with the Canadian provincial securities regulatory authorities in connection with an underwriting agreement led by BMO Capital Markets and includes Canaccord Capital, National Bank Financial, Desjardins Securities and Jennings Capital. Under the terms of the agreement, the underwriters will buy 3.5 million common shares and sell them to the public at a price of $8.50 per share, which will net $29.75 million. The firm also has granted the underwriters an overallotment option to purchase an additional 350,000 common shares at the same price. Closing is expected to occur about Feb. 13 and is subject to customary closing conditions.

• Vitro Biopharma Inc., of Aurora, Colo., said it has completed a $500,000 private placement to support the completion of the development and commercial launch of its stem cell-derived human beta islets. The investment includes an initial sale of 1.25 million shares of common stock for $125,000, along with warrants to purchase up to an additional 2 million shares of common stock exercisable in tranches.